Genocea Biosciences, Inc.

LSE:0A51 Stock Report

Market Cap: US$5.9k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Genocea Biosciences Management

Management criteria checks 2/4

Key information

Chip Clark

Chief executive officer

US$3.8m

Total compensation

CEO salary percentage15.2%
CEO tenure12.3yrs
CEO ownershipn/a
Management average tenure7.3yrs
Board average tenure8.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chip Clark's remuneration changed compared to Genocea Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2022n/an/a

-US$37m

Dec 31 2021US$4mUS$571k

-US$33m

Sep 30 2021n/an/a

-US$35m

Jun 30 2021n/an/a

-US$36m

Mar 31 2021n/an/a

-US$43m

Dec 31 2020US$1mUS$551k

-US$44m

Sep 30 2020n/an/a

-US$38m

Jun 30 2020n/an/a

-US$41m

Mar 31 2020n/an/a

-US$36m

Dec 31 2019US$1mUS$533k

-US$39m

Sep 30 2019n/an/a

-US$29m

Jun 30 2019n/an/a

-US$30m

Mar 31 2019n/an/a

-US$27m

Dec 31 2018US$1mUS$515k

-US$28m

Sep 30 2018n/an/a

-US$39m

Jun 30 2018n/an/a

-US$48m

Mar 31 2018n/an/a

-US$59m

Dec 31 2017US$2mUS$493k

-US$57m

Sep 30 2017n/an/a

-US$62m

Jun 30 2017n/an/a

-US$58m

Mar 31 2017n/an/a

-US$54m

Dec 31 2016US$1mUS$455k

-US$50m

Compensation vs Market: Chip's total compensation ($USD3.75M) is above average for companies of similar size in the UK market ($USD351.24K).

Compensation vs Earnings: Chip's compensation has increased whilst the company is unprofitable.

CEO

Chip Clark (53 yo)

12.3yrs

Tenure

US$3,750,857

Compensation

Mr. William D. Clark, M.B.A., also known as Chip, has been an Independent Director at iBio, Inc. since August 26, 2021 and serves as its Chairman since November 2022. He has been the Director, Chief Execut...

Leadership Team

NamePositionTenureCompensationOwnership
William Clark
President12.3yrsUS$3.75mno data
Jessica Flechtner
Chief Scientific Officer7.3yrsUS$1.27mno data
Diantha Duvall
CFO & Secretary4.2yrsno datano data

7.3yrs

Average Tenure

50yo

Average Age

Experienced Management: 0A51's management team is seasoned and experienced (7.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
William Clark
President12.3yrsUS$3.75mno data
Kenneth Bate
Independent Chairman of the Board8.7yrsUS$120.98kno data
Michael Higgins
Independent Director8.3yrsUS$78.48kno data
Katrine Bosley
Independent Director10.2yrsUS$75.88kno data
George R. Siber
Independent Chairman of Scientific Advisory Board & Director16.3yrsUS$66.98kno data
Kwok-Kin Wong
Member of Scientific Advisory Boardno datano datano data
Jennifer Herron
Independent Director1.7yrsUS$61.50kno data
Marcela Maus
Member of Scientific Advisory Boardno datano datano data
Eric Tran
Member of Scientific Advisory Boardno datano datano data
Elizabeth Jaffee
Member of Scientific Advisory Boardno datano datano data
John Lunger
Independent Director1.2yrsno datano data

8.7yrs

Average Tenure

53.5yo

Average Age

Experienced Board: 0A51's board of directors are considered experienced (8.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/05/23 00:49
End of Day Share Price 2023/05/22 00:00
Earnings2022/03/31
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Genocea Biosciences, Inc. is covered by 10 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael UlzBaird
Mara GoldsteinCantor Fitzgerald & Co.
Christopher JamesFBR Capital Markets & Co.